Cytokinetics (CYTK) Surpasses FY14 Estimates Following Recent Astellas Deal; Roth Cap. Affirms at 'Buy'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Piper Jaffray Upgrades Cytokinetics (CYTK) to Overweight; Sees 100% Upside
February 13, 2015 6:46 AM ESTPiper Jaffray upgraded Cytokinetics (NASDAQ: CYTK) from Neutral to Overweight with a price target of $13.00 (from $7.00), suggesting 100% upside from current levels.
Analyst Charles Duncan commented, "Cytokinetics reported 4Q/FY14 results yesterday, ending '14 with $83M in cash which combined with inflows already in '15... More
Cytokinetics (CYTK) Tops Q4 EPS Views; Offers FY15 Outlook
February 12, 2015 4:13 PM ESTCytokinetics (NASDAQ: CYTK) reported Q4 EPS of $0.23, $0.40 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $21.8 million versus the consensus estimate of $10.8 million.
Financial Guidance
Cytokinetics also announced its financial guidance for 2015. The company anticipates cash... More
